


## Why RNA molecules make excellent biomarkers


- studying RNA provides better understanding of **dynamic changes** in cell, tissue or organism
- **diversity of RNA** species (different RNA molecules, varying abundance levels and structural differences) opens up new opportunities for improving diagnosis and treatment of human disease:
- RNA **captures heterogeneity** and varying disease states
- RNA measurement **technologies** are ready to develop a **clinical-grade test**: they are sensitive, high-throughput and capable of measuring a large dynamic range
- RNA measurement technologies allow **easy multiplexing**: mutli-gene signatures outperform single biomarkers;
- RNA molecules are an untapped source of biomarkers leading to an attractive **intellectual property** landscap



## How Biogazelle and DNALytics unlock the potential of +80,000 candidate biomarkers in your samples

Biogazelle & DNALytics offer an end-to-end solution from RNA biomarker panel discovery (multigene signature) to the development of a clinical-grade test. In this partnership, Biogazelle coordinates the projects and manages all data production aspects while DNALytics provides guidance and implements data analysis and modeling aspects.

This RNA biomarker discovery and validation program comprise **3 phases** (shown in pink) covering **7 steps** (shown in blue).



## Why the Biogazelle & DNALytics biomarker development platform is your best choice

- **smoother** projects due to aligned wet and dry lab workflows: all steps – from RNA sequencing over advanced data modeling to qPCR validation – are managed by one partner
- **faster** delivery of results due to alignment of results: no misalignment or misinterpretation of results by multiple parties
- **higher quality** of resulting biomarker due to 15 years of experience in transcriptome analysis and model building
- **more efficient** projects with one point of contact for the entire biomarker development program

